Lidocaine Infusion in Pancreatic Cancer

Eligibility Criteria

• 1. Has histologically or cytologically confirmed adenocarcinoma of the pancreas that is considered resectable as well as other types of pancreatic cancer (malignant endocrine and exocrine tumors)
• 2. Has measurable disease, defined as at least 1 tumor that fulfills the criteria
• 3. Patients diagnosed with resectable cancer, but upon initial phase of surgical exploration found to have metastatic disease
• 4. Has read, understood and signed the informed consent form (ICF) approved by the Independent Review Board/Independent Ethics Committee (IRB/IEC)
• 5. Prior systemic treatments for metastatic disease are permitted, including targeted therapies, biologic response modifiers, chemotherapy, hormonal therapy, or investigational therapy.
• 1. Has American Society of Anesthesiologists (ASA) physical status \> 3
• 2. Has hypersensitivity or allergy to amide-linked local anesthetics
• 3. Has a second or third degree heart block
• 4. Has severe sinoatrial block
• 5. Is currently being treated with any of the following class I antiarrhythmic drugs; quinidine, flecainide, disopyramide, or procainamide
• 6. Has been treated with amiodarone in the past
• 7. Has Adams-Stoke syndrome
• 8. Has Wolff-Parkinson-White syndrome
• 9. Has a history of blood clots, pulmonary embolism, or deep vein thrombosis unless controlled by anticoagulant treatment
• 10. Has a known history of human immunodeficiency virus (HIV) positivity or untreated and uncontrolled hepatitis B or C